IL321614A - Combination cancer treatment with an antibody that binds at least EGFR and an immune checkpoint inhibitor - Google Patents

Combination cancer treatment with an antibody that binds at least EGFR and an immune checkpoint inhibitor

Info

Publication number
IL321614A
IL321614A IL321614A IL32161425A IL321614A IL 321614 A IL321614 A IL 321614A IL 321614 A IL321614 A IL 321614A IL 32161425 A IL32161425 A IL 32161425A IL 321614 A IL321614 A IL 321614A
Authority
IL
Israel
Prior art keywords
egfr
cancers
binds
antibody
immune checkpoint
Prior art date
Application number
IL321614A
Other languages
English (en)
Hebrew (he)
Inventor
Ernesto Isaac Wasserman
Eduardo Jose Pennella
Original Assignee
Merus Nv
Ernesto Isaac Wasserman
Eduardo Jose Pennella
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv, Ernesto Isaac Wasserman, Eduardo Jose Pennella filed Critical Merus Nv
Publication of IL321614A publication Critical patent/IL321614A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL321614A 2022-12-23 2025-06-19 Combination cancer treatment with an antibody that binds at least EGFR and an immune checkpoint inhibitor IL321614A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2033821 2022-12-23
PCT/NL2023/050684 WO2024136658A1 (en) 2022-12-23 2023-12-22 Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor

Publications (1)

Publication Number Publication Date
IL321614A true IL321614A (en) 2025-08-01

Family

ID=85172568

Family Applications (1)

Application Number Title Priority Date Filing Date
IL321614A IL321614A (en) 2022-12-23 2025-06-19 Combination cancer treatment with an antibody that binds at least EGFR and an immune checkpoint inhibitor

Country Status (10)

Country Link
US (1) US20260217836A1 (cg-RX-API-DMAC10.html)
EP (1) EP4637817A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025542384A (cg-RX-API-DMAC10.html)
KR (1) KR20250124833A (cg-RX-API-DMAC10.html)
CN (2) CN120583961A (cg-RX-API-DMAC10.html)
AU (1) AU2023408531A1 (cg-RX-API-DMAC10.html)
IL (1) IL321614A (cg-RX-API-DMAC10.html)
MX (1) MX2025007322A (cg-RX-API-DMAC10.html)
TW (1) TW202432605A (cg-RX-API-DMAC10.html)
WO (1) WO2024136658A1 (cg-RX-API-DMAC10.html)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
EP3456191A1 (en) 2008-06-27 2019-03-20 Merus N.V. Antibody producing non-human mammals
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
TWI717401B (zh) 2015-10-20 2021-02-01 南韓商東友精細化工有限公司 整合有偏光板之窗口基板、及製備該窗口基板之方法
JP7296728B2 (ja) * 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
IL303633A (en) * 2020-12-15 2023-08-01 Merus Nv Cancer treatment with an antibody that binds LGR5 and EGFR
CN120504741A (zh) * 2021-10-06 2025-08-19 美勒斯公司 使用至少结合egfr的抗体治疗免疫检查点抑制剂治疗的具高egfr表达的癌症

Also Published As

Publication number Publication date
EP4637817A1 (en) 2025-10-29
KR20250124833A (ko) 2025-08-20
TW202432605A (zh) 2024-08-16
CN122031678A (zh) 2026-05-15
AU2023408531A1 (en) 2025-07-17
US20260217836A1 (en) 2026-07-30
JP2025542384A (ja) 2025-12-25
WO2024136658A1 (en) 2024-06-27
CN120583961A (zh) 2025-09-02
MX2025007322A (es) 2025-07-01

Similar Documents

Publication Publication Date Title
IL313807A (en) Claudin 18 antibodies and methods for cancer treatment
MX2022003005A (es) Composiciones y metodos de anticuerpos anti-cd39.
IL290123A (en) Combined treatment including antibodies against claudin 18.2 and immune checkpoint inhibitors for cancer treatment
MX2024011278A (es) Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer.
MX2022008421A (es) Anticuerpo anti-galectina-9 y usos del mismo.
SG11202009986QA (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
SG11202010993VA (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
IL292662A (en) Methods for treating cancer with a combination of an anti-pd-1 antibody and a drug-anti-tissue factor antibody conjugate
IL314678A (en) Bispecific antibodies against cd277 and a tumor-antigen
ZA201907754B (en) Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
MX2022006728A (es) Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario.
IL311548A (en) Treatment of cancer treated with an immune checkpoint inhibitor and with high EGFR expression by an antibody that binds at least EGFR
HK40125978A (en) Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor
CA3277758A1 (en) Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor
EP4104855A4 (en) USE OF AN ANTI-PD-1 ANTIBODY IN THE TREATMENT OF NEUROENDOCRINE TUMORS
MX2022006148A (es) Metodos para tratamiento del cancer usando anticuerpos anti-ox40 en combinacion con anticuerpos anti-tigit.
IL325396A (en) Anti-gpc3 antibody or antigen-binding fragment and their use
IL313864A (en) Methods for treating recurrent ovarian cancer using bispecific antibodies against MUC16 and against CD3 alone or in combination with antibodies against PD-1
MX2022013182A (es) Tratamiento de cánceres con un anticuerpo que se une a lgr5 y egfr.
IL317449A (en) Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
IL290247A (en) Cancer treatment by a combination of an antibody against lgr5 and egfr and an inhibitor of topoisomerase i
HK40107286A (en) Treatment of immune checkpoint inhibitor-treated cancers with high egfr expression using an antibody that binds at least egfr
MX2023011796A (es) Métodos de tratamiento del cáncer con anticuerpos inmunorreceptor de células t con dominios ig e itim (anti-tigit).
MX2023013574A (es) Combinacion farmaceutica que comprende un anticuerpo anti-cd205 y un inhibidor del punto de control.
CA3273665A1 (en) Methods of treating cancer using anti-ddr1 antibodies and immune checkpoint inhibitors